Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants aged 2 months (42-98 days) at time of enrolment.~* Available for the entire study period and whose parent/legal guardian can be reached by telephone.~Exclusion Criteria:~* Previous vaccination with licensed or investigational pneumococcal vaccine.~* A previous anaphylactic reaction to any vaccine or vaccine-related component.~* Contraindication to vaccination with a pneumococcal conjugate vaccine.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 98 Days
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): 13 valent pneumococcal conjugate vaccine
- 2 (Type: ACTIVE_COMPARATOR): 7 valent pneumococcal conjugate vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).